Related Experiment Videos
Bone marrow transplantation for Fanconi anemia
E Gluckman1, A D Auerbach, M M Horowitz
1International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee 53226, USA.
Blood
|October 1, 1995
Summary
Bone marrow transplants offer effective Fanconi anemia treatment. Younger age, higher platelets, and specific conditioning regimens improve survival, especially with sibling donors, suggesting earlier intervention is beneficial.
Area of Science:
- Hematology
- Genetics
- Oncology
Background:
- Fanconi anemia is a severe genetic disorder causing bone marrow failure and cancer risk.
- Bone marrow transplantation is a key treatment, but transplant outcome factors need clarification.
Purpose of the Study:
- To analyze factors influencing bone marrow transplant outcomes in Fanconi anemia patients.
- To identify patient, disease, and treatment variables associated with survival post-transplant.
Main Methods:
- Retrospective analysis of 199 bone marrow transplants for Fanconi anemia (1978-1994) from the International Bone Marrow Transplant Registry.
- Cox proportional hazards regression used to determine factors affecting survival.
- Comparison of outcomes between HLA-identical sibling and alternative donor transplants.
Main Results:
- Two-year survival was 66% for sibling transplants versus 29% for alternative donor transplants.
- Factors associated with improved survival included younger patient age, higher pretransplant platelet counts, and specific conditioning regimens (low-dose cyclophosphamide/irradiation) and GVHD prophylaxis (cyclosporine).
- Antithymocyte globulin use also correlated with better survival outcomes.
Conclusions:
- Bone marrow transplantation is an effective therapy for Fanconi anemia.
- Early intervention is recommended due to the negative impact of age and low platelet counts on transplant outcomes.
- Optimizing conditioning and GVHD prophylaxis can enhance transplant success in Fanconi anemia patients.